INOVIQ ORD
INOVIQ Secures Global Rights to Novel Ovarian Cancer Biomarker Technology
INOVIQ (ASX: IIQ) has strengthened its ovarian cancer program by licensing exclusive worldwide rights to novel exosomal biomarker intellectual property from UniQuest, the commercialisation arm of The University of Queensland. The agreement gives INOVIQ the freedom to develop and commercialise the biomarkers as part of its EXO-OC test, a blood test for the early detection and […]
INOVIQ reports 88% kill rate of breast and lung cancer cells in CAR-exosome therapy study
INOVIQ (ASX: IIQ) has reported superior efficacy from an in vitro study of CAR-exosomes cancer therapy that killed almost 88% of triple-negative breast cancer (TNBC) and lung cancer cells within 96 hours. Real-time cell analysis demonstrated that CAR-NK-EVs — chimeric antigen receptor natural killer cells derived from extracellular vesicles — exerted a significant cytotoxic effect […]
Market wrap: falling rates lead to fast rising share market
Interest rates down, share prices up. If that sounds like a simple formula then it certainly is but the proof is in the pudding as the Australian market put in its best week this year in the lead up to a holiday weekend. No sooner had central banks in Canada and Europe announced the first […]
INOVIQ study confirms breakthrough exosome therapy in the treatment of breast cancer
Biotechnology company INOVIQ (ASX: IIQ) has produced and isolated engineered exosomes (EEVs) to target and kill breast cancer cells in vitro using its proprietary EXO-ACE technology. The breakthrough therapy has been validated in a proof-of-concept study in which a chimeric antigen receptor (CAR) was developed for the targeted delivery of therapeutic EEVs to cancer cells. […]